LSE : 0ILL.L

Laboratorios Farmaceuticos Rovi, S.A.

$57.25 EUR

$0.95 (1.69%)

Volume
2.75K
Average Volume
11.27K
Market Capitalization
$2.93B
P/E Ratio
22.28
Dividend Yield
1.68%
Price Target
Year High
$79.76
Year Low
$37.14
Day High
—
Day Low
—
Payout Ratio
$0.36
Current Ratio
$3.66
Company Overview

LSE

Juan Lopez-Belmonte Encina

Drug Manufacturers - Specialty & Generic

Healthcare

0ILL.L

2197

ES

EUR

https://www.rovi.es

34 91 021 30 00

E6996D109

N/A

Liquidity Metrics

0.17

3.66

1.80

0.66

0.36

Sales & Valuation

$743.48M

3.95

4.35

25.50

2.24

Profitability

$2.75

$140.44M

17.79%

23.30%

20.89%

14.23%

P/E Metrics

22.28

-0.62

-0.62

Analyst Price Target & Rating

Buy

4/5

0 Analysts

%

Financial Health Scores

9.75

5/9

$391.75M

$926.32M

$239.58M

$168.66M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
María Álvarez Solas Chief Operating Officer
Rosario Perucha Pérez Marketing Director
Ivan Jorge Lopez-Belmonte Encina Second Deputy Chairman and Chief Commercial & Development Officer
Juan Lopez-Belmonte Encina Chairman & Chief Executive Officer
Miguel Ángel Ortega Sánchez Chief Industrial Officer
Mercedes Benítez del Castillo Sánchez Chief Legal Officer
Alicia Hurtado Morales Chief Compliance Officer
Francisco Javier Angulo García Human Resources Manager
Javier Lopez-Belmonte Encina First Deputy Chairman, GM of Industrial Operations & Chief Financial Officer
Marta Campos Martínez Head of Investor Relations
Poll Results

No votes yet today — be the first to share your view!

About Laboratorios Farmaceuticos Rovi, S.A. (LSE:0ILL.L) Stock

Laboratorios Farmacéuticos Rovi, S.A. is a Spanish pharmaceutical enterprise that specializes in the research, development, manufacturing, and global commercialization of its own medicinal products. The company's operations span Spain, the European Union, OECD countries, and various international markets. In addition to its proprietary portfolio, Rovi also distributes pharmaceutical products under license from other laboratories. Its comprehensive product range addresses diverse medical requirements. Key offerings include Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins vital for the prevention and management of venous thromboembolic disease. Neparvis is prescribed for adult patients experiencing symptomatic chronic heart failure with reduced ejection fraction. To ... aid in the dietary management of hypercholesterolemia, Rovi provides Absorcol, Vytorin, and Orvatez. For the maintenance treatment of chronic obstructive pulmonary diseases (COPD), the company offers the long-acting bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa assists men with benign prostatic hyperplasia (BPH) who exhibit moderate to severe storage and voiding symptoms and have not adequately responded to monotherapy. Furthermore, Medikinet and Medicebrán are available for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Rovi also supplies an array of specialized hospital products for imaging diagnostics. These include contrast agents such as Iomeron and Iopamiro for computed tomography (CT) and interventional procedures; Multihance and Prohance for magnetic resonance imaging (MRI); and Sonovue for ultrasounds. The company additionally offers advanced contrast injection systems like EmpowerCTA+, EmpowerMR, and CT Exprès, along with their compatible disposable materials. Beyond its prescription medications, Rovi produces non-prescription pharmaceutical items and delivers contract manufacturing services to other businesses. These services encompass a wide spectrum of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves a broad clientele, including wholesalers, medical professionals, nursing staff, pharmacists, and directly to patients. Notably, Laboratorios Farmacéuticos Rovi, S.A. maintains a significant manufacturing collaboration with Moderna, Inc. for their mRNA COVID-19 vaccine candidate. Established in 1946 with its headquarters in Madrid, Spain, Laboratorios Farmacéuticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.

Frequently Asked Questions

What is the current Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L) stock price?

Laboratorios Farmaceuticos Rovi, S.A.(LSE:0ILL.L) stock price is $57.25 in the last trading session. During the trading session, 0ILL.L stock reached the peak price of $79.76117 while $37.14 was the lowest point it dropped to. The percentage change in 0ILL.L stock occurred in the recent session was 1.69% while the dollar amount for the price change in 0ILL.L stock was $0.95.

0ILL.L's industry and sector of operation?

The LSE listed 0ILL.L is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of 0ILL.L?

María Álvarez Solas | Chief Operating Officer
Rosario Perucha Pérez | Marketing Director
Ivan Jorge Lopez-Belmonte Encina | Second Deputy Chairman and Chief Commercial & Development Officer
Juan Lopez-Belmonte Encina | Chairman & Chief Executive Officer
Miguel Ángel Ortega Sánchez | Chief Industrial Officer

How many employees does 0ILL.L have?

Number of 0ILL.L employees currently stands at 2197. 0ILL.L operates from Calle José Isbert, 2, Madrid, MA 28223, ES.

Link for 0ILL.L official website?

Official Website of 0ILL.L is: https://www.rovi.es

How do I contact 0ILL.L?

0ILL.L could be contacted at phone #34 91 021 30 00 and can also be accessed through its website. 0ILL.L operates from Calle José Isbert, 2, Madrid, MA 28223, ES.

How many shares of 0ILL.L are traded daily?

The average number of 0ILL.L shares traded daily for last 3 months was 11.27K.

What is the market cap of 0ILL.L currently?

The market value of 0ILL.L currently stands at $2.93B with its latest stock price at $57.25